The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): Experience with 77 patients

Clinical Nuclear Medicine

Volumn 38, Issue 2, 2013, Pages

  Nanni, Cristina ^a   Zamagni, Elena ^b   Celli, Monica ^a   Caroli, Paola ^a   Ambrosini, Valentina ^a   Tacchetti, Paola ^b   Brioli, Annamaria ^b   Zannetti, Beatrice ^b   Pezzi, Annalisa ^b   Pantani, Lucia ^b   Perrone, Giulia ^b   Zompatori, Maurizio ^c   Cavo, Michele ^b   Colletti, Patrick M ^d   Rubello, Domenico ^e   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Seràgnoli Institute of Hematology   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Santa Maria della Misericordia Hospital   (Italy)

Author keywords

autotransplantation; FDG PET CT; multiple myeloma; prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROSPECTIVE STUDY; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CLINICAL TRIAL; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; STEM CELL TRANSPLANTATION;

FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

MLCS; MLOWN;

EID: 84872902451     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318266cee2     Document Type: Article

References (21)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336: 1657-1664
2. Bataille R, Manolagas SC, Berenson Jr. Pathogenesis and management of bone lesions in multiplemyeloma. Hematol Oncol Clin North Am. 1997;11:349-361 (Pubitemid 27193730)
3. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol. 2003;123: 758-769 (Pubitemid 37533288)
4. Mitsiades CS, Mitsiades N, Munshi NC, et al. Focus on multiple myeloma. Cancer Cell. 2004;6:439-444 (Pubitemid 39469979)
5. Jemal A, Thomas A, Nurray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23-47
6. Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years: Report of 10 cases and review of the literature. Arch Intern Med. 1996;156:1463-1468 (Pubitemid 26226942)
7. Hallek M, Bergsagel PF, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood. 1998;91:3-21 (Pubitemid 28018724)
8. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am. 1992;6:273-284
9. Schwartz GG. Multiple myeloma: Clusters, clues, and dioxins. Cancer Epidemiol Biomarkers Prev. 1997;6:49-56 (Pubitemid 27030427)
10. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey. Br J Haematol. 1999;106:35-39 (Pubitemid 29343524)
11. Umeda M, Adachi Y, Tomiyama J, et al. Bone lesions in elderly multiple myeloma. Nippon Ronen Igakkai Zasshi. 2002;39:631-638
12. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154:32-75
13. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. International Myeloma Workshop Consensus Panel 3. Blood. 2011;117:4701-4705
14. Bartel TB, Haessler J, Brown TL, et al. F18-Fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-2076
15. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Reviewand 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35:1773-1782 (Pubitemid 29512308)
16. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57-65
17. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118:5989-5995
18. Durie BG, Kyle RA, Belch A, et al. Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379-398. Erratum in: Hematol J. 2004;5:285 (Pubitemid 38088783)
19. Haznedar R, Ak? SZ, Akdemir OU, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival inmultiplemyeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046-1053
20. Elliott BM, Peti S, Osman K, et al. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol. 2011;86:289-298
21. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002 Mar;29:361-366 (Pubitemid 34253248)